EIKON THERAPEUTICS INC (EIKN) Fundamental Analysis & Valuation

NASDAQ:EIKN • US2825641036

Current stock price

9.68 USD
+0.06 (+0.68%)
At close:
9.68 USD
0 (0%)
After Hours:

This EIKN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EIKN Profitability Analysis

1.1 Basic Checks

  • In the past year EIKN has reported negative net income.
  • In the past year EIKN has reported a negative cash flow from operations.
EIKN Yearly Net Income VS EBIT VS OCF VS FCFEIKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -56.10%, EIKN perfoms like the industry average, outperforming 42.33% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -118.13%, EIKN is doing worse than 60.39% of the companies in the same industry.
Industry RankSector Rank
ROA -56.1%
ROE -118.13%
ROIC N/A
ROA(3y)-50.59%
ROA(5y)N/A
ROE(3y)-91.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EIKN Yearly ROA, ROE, ROICEIKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EIKN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EIKN Yearly Profit, Operating, Gross MarginsEIKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. EIKN Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EIKN has about the same amount of shares outstanding.
  • EIKN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EIKN Yearly Shares OutstandingEIKN Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 2025 10M 20M 30M 40M 50M
EIKN Yearly Total Debt VS Total AssetsEIKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • EIKN has an Altman-Z score of -2.45. This is a bad value and indicates that EIKN is not financially healthy and even has some risk of bankruptcy.
  • EIKN has a Altman-Z score of -2.45. This is comparable to the rest of the industry: EIKN outperforms 46.99% of its industry peers.
  • EIKN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.45
ROIC/WACCN/A
WACCN/A
EIKN Yearly LT Debt VS Equity VS FCFEIKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 6.34 indicates that EIKN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.34, EIKN is in the better half of the industry, outperforming 63.69% of the companies in the same industry.
  • A Quick Ratio of 6.34 indicates that EIKN has no problem at all paying its short term obligations.
  • EIKN has a Quick ratio of 6.34. This is in the better half of the industry: EIKN outperforms 64.27% of its industry peers.
Industry RankSector Rank
Current Ratio 6.34
Quick Ratio 6.34
EIKN Yearly Current Assets VS Current LiabilitesEIKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EIKN Growth Analysis

3.1 Past

  • EIKN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.84%.
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, EIKN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.30% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.85%
EPS Next 2Y38.39%
EPS Next 3Y24.22%
EPS Next 5Y14.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EIKN Yearly Revenue VS EstimatesEIKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
EIKN Yearly EPS VS EstimatesEIKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. EIKN Valuation Analysis

4.1 Price/Earnings Ratio

  • EIKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EIKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EIKN Price Earnings VS Forward Price EarningsEIKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EIKN Per share dataEIKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

  • EIKN's earnings are expected to grow with 24.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.39%
EPS Next 3Y24.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EIKN Dividend Analysis

5.1 Amount

  • No dividends for EIKN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EIKN Fundamentals: All Metrics, Ratios and Statistics

EIKON THERAPEUTICS INC

NASDAQ:EIKN (5/1/2026, 8:23:31 PM)

After market: 9.68 0 (0%)

9.68

+0.06 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners22.9%
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner Change8.21%
Market Cap524.08M
Revenue(TTM)N/A
Net Income(TTM)-333.64M
Analysts78.33
Price Target25.25 (160.85%)
Short Float %8.48%
Short Ratio9.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.86
P/tB 1.86
EV/EBITDA N/A
EPS(TTM)-6.18
EYN/A
EPS(NY)-6.74
Fwd EYN/A
FCF(TTM)-4.35
FCFYN/A
OCF(TTM)-3.48
OCFYN/A
SpS0
BVpS5.22
TBVpS5.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -56.1%
ROE -118.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.59%
ROA(5y)N/A
ROE(3y)-91.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 247.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.34
Quick Ratio 6.34
Altman-Z -2.45
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)354.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.68%
EPS Next Y90.85%
EPS Next 2Y38.39%
EPS Next 3Y24.22%
EPS Next 5Y14.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.21%
EBIT Next 3Y-14.23%
EBIT Next 5YN/A
FCF growth 1Y-7.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.85%
OCF growth 3YN/A
OCF growth 5YN/A

EIKON THERAPEUTICS INC / EIKN Fundamental Analysis FAQ

What is the fundamental rating for EIKN stock?

ChartMill assigns a fundamental rating of 2 / 10 to EIKN.


What is the valuation status for EIKN stock?

ChartMill assigns a valuation rating of 1 / 10 to EIKON THERAPEUTICS INC (EIKN). This can be considered as Overvalued.


What is the profitability of EIKN stock?

EIKON THERAPEUTICS INC (EIKN) has a profitability rating of 0 / 10.